Peptide library › Immune & inflammation
Zilucoplan
Also known as Zilbrysq
Daily self-injected peptide for generalised myasthenia gravis, an autoimmune condition that causes muscle weakness.
What people use it for
- Generalised myasthenia gravis in adults with acetylcholine receptor antibodies
What Zilucoplan does in the body
A ring-shaped peptide that blocks complement C5, stopping the immune damage at the junction between nerves and muscles.
Strength of evidence
Strong: the Phase 3 RAISE trial improved daily function and muscle strength.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Meningococcal infection (serious, rare)
- Injection-site reactions
- Upper respiratory infections
- Diarrhoea
Who should avoid it or take extra care
- Unresolved meningococcal infection
- Not vaccinated against meningococcal disease
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2023. Carries a boxed warning for serious meningococcal infections; meningococcal vaccines are required and it's only available through a safety programme.
How it's taken
Route: Injection under the skin, once daily
How long it lasts (half-life): About 7 to 8 days
Latest research & news
- Current and Emerging Therapies for Generalized Myasthenia Gravis: Toward Precision Medicine
Research · Review · PubMed · Neurol Ther · 21 Nov 2026 - Successful Treatment of Pembrolizumab-associated Myositis-myocarditis-myasthenia Gravis Overlap Syndrome with Gastrointestinal Pseudo-obstruction Using Zilucoplan: A Case Report
Research · Study · PubMed · Intern Med · 19 Nov 2026 - Zilucoplan as Plan B-Complement Inhibition as Rescue Therapy for Refractory Myasthenic Crisis in Thymomatous Myasthenia Gravis
Research · Case report · PubMed · Muscle Nerve · 17 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Zilucoplan privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Zilucoplan in Fiala How to installMore in Immune & inflammation
- Thymosin Alpha-1Thymus-derived immune-modulating peptide approved in several countries.
- LL-37The only human cathelicidin: an antimicrobial peptide made by the immune system.
- KPVAnti-inflammatory tripeptide taken from the end of alpha-MSH.
- VIPNeuropeptide that relaxes blood vessels and calms immune responses.
- ARA-290Peptide derived from erythropoietin (EPO), studied for nerve pain and inflammation without raising red blood cells.
- CyclosporineRing-shaped peptide from a fungus that suppresses the immune system; used after transplants and for psoriasis, arthritis and dry eye.
- ThymulinNatural thymus hormone sold online for immune support and hair growth; no modern human trials.
- NangibotideExperimental drip for septic shock that aims to calm an overactive immune response; it missed its main trial goal.
- EcallantideInjection that stops attacks of hereditary angioedema, a rare condition causing sudden severe swelling.
- IcatibantSelf-injected treatment for sudden swelling attacks in hereditary angioedema.